Search Result

Pathways Recommended:	Antibody-drug Conjugate/ADC Related

Results for "

IgG1-κ antibody

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (4) Antibody-Drug Conjugates (ADCs) (4) Amyloid-β (1) Apoptosis (2) Bacterial (2) c-Fms (1) CD276/B7-H3 (1) CD38 (1) CD73 (1) CTLA-4 (2) EGFR (2) Ephrin Receptor (1) Filovirus (1) HIV (1) IFNAR (2) IGF-1R (1) Influenza Virus (1) Interleukin Related (9) LAG-3 (1) Microtubule/Tubulin (2) MMP (1) Notch (1) PD-1/PD-L1 (4) Phosphatase (1) RSV (1) SARS-CoV (3) TAM Receptor (2) Tau Protein (1) Tim3 (1) TNF Receptor (5) Topoisomerase (1) VEGFR (1)
By Research Areas:	Cancer (41) Infection (14) Inflammation/Immunology (23) Metabolic Disease (3) Neurological Disease (3)

By Targets:

ADC Antibody (4)

Antibody-Drug Conjugates (ADCs) (4)

Amyloid-β (1)

Apoptosis (2)

Bacterial (2)

c-Fms (1)

CD276/B7-H3 (1)

CD38 (1)

CD73 (1)

CTLA-4 (2)

EGFR (2)

Ephrin Receptor (1)

Filovirus (1)

HIV (1)

IFNAR (2)

IGF-1R (1)

Influenza Virus (1)

Interleukin Related (9)

LAG-3 (1)

Microtubule/Tubulin (2)

MMP (1)

Notch (1)

PD-1/PD-L1 (4)

Phosphatase (1)

RSV (1)

SARS-CoV (3)

TAM Receptor (2)

Tau Protein (1)

Tim3 (1)

TNF Receptor (5)

Topoisomerase (1)

VEGFR (1)

By Research Areas:

Cancer (41)

Infection (14)

Inflammation/Immunology (23)

Metabolic Disease (3)

Neurological Disease (3)

Inhibitors & Agonists

130

Inhibitory Antibodies

Targets Recommended: ADC Antibody Antibody-Drug Conjugates (ADCs) ADC Linker PROTAC-Linker Conjugates for PAC

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P9997

Rosnilimab ANB030	PD-1/PD-L1	Cancer
Rosnilimab is a humanized IgG1-κ antibody targeting to PD-1 .

HY-P9999

Trontinemab RG6102; RO-7126209	Amyloid-β	Neurological Disease
Trontinemab is a bispecific and humanizedized IgG1-κ antibody, targeting to amyloid beta A4 precursor protein (APP) and transferrin receptor, p90, CD71 (TFRC). Trontinemab can be used for research on Alzheimer disease (AD) .

HY-P9993

Peresolimab LY-3462817	PD-1/PD-L1	Cancer
Peresolimab is a humanized IgG1-κ antibody targeting to PD-1. Peresolimab potentially stimulates physiological immune inhibitory pathways to restore immune homeostasis .

HY-P9988

Mecbotamab BA301	ADC Antibody TAM Receptor	Cancer
Mecbotamab is a humanized IgG1-κ antibody targeting to AXL receptor tyrosine kinase (AXL). Mecbotamab can serves as a conditionally active biologic (CAB), which can be conjugated with MMAE (HY-15162) via a cleavable linker, to form ADC Mecbotamab vedotin (BA3011) .

HY-P990038

Eurestobart	Phosphatase	Neurological Disease
Eurestobart is a humanized IgG1κ antibody targeting ENTPDase.

HY-P99888

Pimurutamab	EGFR	Others
Pimurutamab is a humanized IgG1-κ antibody targeting EGFR. Mainly expressed by CHO-K1 cells .

HY-P99892

Serclutamab PR-1594407; DC-1630423	EGFR	Others
Serclutamab is a humanized chimeric antibody targeting EGFR IgG1-κ. Mainly expressed by CHO (Chinese Hamster Ovary) cells .

HY-P990057

Picankibart	Interleukin Related	Cancer
Picankibart is a mouse-derived IgG1κ antibody targeting IL23A .

HY-164134

Human IgG1 kappa, Isotype Control conjugated with MMAE	Antibody-Drug Conjugates (ADCs)	Cancer
Human IgG1 kappa, Isotype Control conjugated with MMAE is a human monoclonal antibody that is an isotype control of human IgG1κ antibody and has an inhibitory effect on tubulin polymerization. Human IgG1 kappa, Isotype Control conjugated with MMAE can be used to synthesize antibody conjugate molecules (ADCs) .

HY-P99864

Dovanvetmab ZTS-00521505	Interleukin Related	Others
Dovanvetmab (ZTS-00521505) is an IgG1-κ antibody targeting Felcat IL31. Mainly expressed by CHO (Chinese Hamster Ovary) cells .

HY-P990024

Casdozokitug SRF-388	Interleukin Related	Cancer
Casdozokitug (SRF-388) is an IgG1κ antibody targeting IL27 .

HY-P99104

Plutavimab COVI-AMG; STI-2020	SARS-CoV	Infection
Plutavimab a human IgG1-κ anti-SARS-CoV-2 antibody, targeting to Spike (S) glycoprotein receptor binding domain (RBD) .

HY-P99699

Lesofavumab MHAB5553A; RG70026	Influenza Virus	Infection
Lesofavumab (MHAB5553A) is a human IgG1κ anti-influenza B virus antibody .

HY-P9995

Posdinemab JNJ-63733657	Tau Protein	Cancer
Posdinemab is a humanized IgG1κ antibody, targeting to microtubule-associated protein tau (MAPT) .

HY-P9909

Ustekinumab 1 Publications Verification Anti-Human IL-12/IL-23, Human antibody	Interleukin Related	Inflammation/Immunology
Ustekinumab is an anti-IL-12/IL-23 IgG1κ human monoclonal antibody.

HY-P990036

Dazukibart	IFNAR	Infection
Dazukibart is a mouse-derived, humanized IgG1κ antibody targeting interferon beta 1 (IFNB1) .

HY-P990082

Suvemcitug	VEGFR	Cancer
Suvemcitug is a humanized IgG1κ antibody targeting VEGF derived from the African hare (Oryctolagus cuniculus) .

HY-P990018

Boserolimab MK-5890	TNF Receptor	Cancer
Boserolimab (MK-5890) is a chimeric humanized IgG1κ antibody targeting the mouse signaling regulatory protein CD27.

HY-P99615

Felvizumab SB 209763; RSHZ19	RSV	Infection
Felvizumab (SB 209763) is a humanized IgG1κ monoclonal antibody directed to distinct neutralizing epitopes on the F glycoprotein of RSV .

HY-P990040

Exlinkibart LVGN-6051	TNF Receptor	Cancer
Exlinkibart (LVGN-6051) targets TNFRSF9 and is an IgG1κ antibody humanized through complementarity-determining region (CDR) grafting technology.

HY-P990007

Tulisokibart PRA023; PRA-023	TNF Receptor	Inflammation/Immunology
Tulisokibart (PRA023) is a humanized IgG1-κ monoclonal antibody targeting to TNFSF15/TL1A. Tulisokibart can be used to study a variety of inflammatory/fibrotic diseases, such as Crohn's Disease (CD) .

HY-P99368

Lacnotuzumab MCS110; Anti-Human B7-H3	c-Fms	Metabolic Disease Cancer
Lacnotuzumab (MCS110) is a neutralizing humanized IgG1/κ monoclonal antibody targeting CSF-1 that prevents CSF-1 from activating the CSF-1R. Lacnotuzumab can be used for the research of pigmented villonodular synovitis .

HY-P990041

Firastotug	CTLA-4	Inflammation/Immunology Cancer
Firastotug is an IgG1κ antibody targeting CTLA4. CTLA4 is a cytotoxic T lymphocyte-associated protein and a key immune checkpoint in the fields of autoimmunity and cancer .

HY-P99316

Sirukumab CNTO-136	Interleukin Related	Inflammation/Immunology
Sirukumab (CNTO-136) is a human monoclonal anti-IL6 (Interleukin Related) IgG1κ antibody. Sirukumab has the potential for active lupus nephritis research .

HY-P990052

Simaravibart MAD-0004J08	SARS-CoV	Infection
Simaravibart (MAD-0004J08) is an IgG1κ antibody targeting the SARS-CoV2 spike (S) glycoprotein receptor binding domain .

HY-P99040

Onvatilimab JNJ-61610588	PD-1/PD-L1	Cancer
Onvatilimab (JNJ-61610588) is a human IgG1κ anti-VISTA (V-domain Ig Suppressor of T-cell Activation) monoclonal antibody. Onvatilimab has an anti-tumor activity .

HY-P99310

Perakizumab RG4934	Interleukin Related	Inflammation/Immunology
Perakizumab (RG4934) is a humanized IgG1κ monoclonal antibody against IL-17A (Interleukin Related). Perakizumab can be uesd for the research of autoimmune diseases, such as psoriatic arthritis .

HY-P99315

Ruplizumab BG 9588; Anti-Human CD40L Recombinant antibody	TNF Receptor	Inflammation/Immunology
Ruplizumab (BG 9588) is a humanized monoclonal anti-CD40L (TNF Receptor) IgG1κ antibody. Ruplizumab has the potential for systemic lupus erythematosus disease research .

HY-P99181

Mupadolimab CPI-006	CD73	Infection Inflammation/Immunology
Mupadolimab (CPI-006) is an IgG1κ humanized FcγR binding-deficient anti-CD73 monoclonal antibody (mAb) that activates CD73 ^POS B cells .

HY-P99733

Mipasetamab	ADC Antibody TAM Receptor	Cancer
Mipasetamab is an IgG1κ antibody targeting to AXL, a tyrosine kinase receptor and an TAM Receptor. Mipasetamab involves in synthesis of ADCT-601 (Mipasetamab uzoptirine), an AXL-targeted antibody-drug conjugate (ADC). ADCT-601 has anti-tumor activity .

HY-P9901

Ipilimumab 3 Publications Verification MDX-010; BMS-734016	CTLA-4	Cancer
Ipilimumab is a fully human monoclonal antibody IgG1κ that blocks the inhibitory receptor cytotoxic T lymphocyte antigen 4 (CTLA-4) on T cells. Ipilimumab can be used in unresectable or metastatic melanoma (MM) studies .

HY-P990004

Anti-Mouse TIM-3 Antibody (B8.2C12)	Tim3	Cancer
Anti-Mouse TIM-3 Antibody (B8.2C12) is an anti-mouse TIM-3 antibody inhibitor. Anti-Mouse TIM-3 Antibody (B8.2C12) is a rat IgG1κ subtype antibody .

HY-P99313

Quilizumab Anti-Human NGcGM3 Recombinant antibody	Apoptosis	Inflammation/Immunology
Quilizumab (Anti-Human NGcGM3 Recombinant Antibody) is a humanized IgG1κ monoclonal antibody. Quilizumab targets the M1-prime segment of membrane-expressed IgE, leading to depletion of IgE-switched and memory B cells. Quilizumab has the potantial for the asthma research .

HY-P99424

Afasevikumab RG 7624; RO 5553110; NI-1401	Interleukin Related	Inflammation/Immunology
Afasevikumab (RG 7624; RO 5553110; NI-1401) is a fully human monoclonal IgG1κ antibody neutralizing both IL-17A and IL-17F. Afasevikumab has anti-inflammatory activities .

HY-P990046

Tuparstobart Incagn-02385	LAG-3	Inflammation/Immunology
Tuparstobart (Incagn-02385) is an IgG1κ antibody targeting LAG-3. LAG-3 is an immune checkpoint receptor protein mainly expressed on activated T cells, NK cells, B cells and plasmacytoid dendritic cells .

HY-P9998

Semzuvolimab UB421	HIV	Cancer
Semzuvolimab is a murine IgG1κ antibody, targeting to p55, T cell surface antigen T4/Leu-3 (CD4). Murine CD4 antibodies can neutralize HIV infection and have the potential to inhibit HAART stable HIV infection .

HY-P99544

Tagitanlimab HBM-9167; KL-A167	PD-1/PD-L1	Cancer
Tagitanlimab (HBM-9167) is a humanized anti-PD-L1 antibody (IgG1κ type). Tagitanlimab selectively blocks the interaction of PD-L1 and PD-1. Tagitanlimab has the potential to be studied in recurrent or metastatic nasopharyngeal carcinoma (NPC) .

HY-P99669

Iratumumab MDX-060	TNF Receptor	Cancer
Iratumumab (MDX-060) a human anti-CD30 IgG1κ monoclonal antibody. Iratumumab inhibits the growth of CD30-expressing tumor cells. Iratumumab can be used for research of Hodgkin's lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) .

HY-P99655

Ifabotuzumab KB004	Ephrin Receptor Apoptosis	Cancer
Ifabotuzumab (KB004) is an IgG1κ antibody targeting EphA3 (K_D=610 pM). Ifabotuzumab induces tumor cell apoptosis, activates Antibody-dependent cell mediated cytotoxicity (ADCC), and damages tumor vasculature. Ifabotuzumab reduces human idiopathic pulmonary fibrosis (IPF) CCR10 ⁺ cells and improves pulmonary fibrosis .

HY-P99740

Mirzotamab	CD276/B7-H3	Cancer
Mirzotamab is an IgG1κ antibody targeting to CD276/B7-H3. Mirzotamab can conjugates with Clezutoclax (HY-137774), an BCL inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC) .

HY-P99340

Sotrovimab 1 Publications Verification VIR 7831	SARS-CoV	Infection
Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease .

HY-P99583

Suvratoxumab MEDI4893	Bacterial	Infection Inflammation/Immunology
Suvratoxumab (MEDI4893) is a long-acting, high-affinity human anti-α-toxin monoclonal antibody (IgG1κ type). Suvratoxumab potently neutralizes α-toxin, a key S. aureus virulence factor. Suvratoxumab improves survival and reduces lung injury in an immunocompromised mice model of pneumonia. Suvratoxumab also enhances the antibacterial activity of Vancomycin (HY-B0671) or Linezolid (HY-10394) .

HY-P99410

Ordesekimab AMG 714; PRV-015	Interleukin Related	Inflammation/Immunology
Ordesekimab (AMG 714; PRV-015) is a fully human IgG1κ anti-IL-15 (Interleukin Related) monoclonal antibody. The binding of Ordesekimab to IL-15 inhibits the interaction of IL-15 with the IL-2Rβ and common γ chain of the IL-15 receptor complex, but not with the IL-15Rα chain. Ordesekimab has the potential for study of nonresponsive celiac disease (NRCD) .

HY-P990084

Veligrotug	IGF-1R	Cancer
Veligrotug is an IgG1-kappa, anti-IGF1R (insulin-like growth factor 1 receptor, CD221) chimeric monoclonal antibody .

HY-P99238

Rolinsatamab	ADC Antibody	Inflammation/Immunology Cancer
Rolinsatamab is a IgG1κ type chimeric antibody targeting to PRLR (prolactin receptor). Rolinsatamab can be conjugated with pyrrolobenzodiazepine (PDB) dimer SGD-1882 (HY-101127) via a cleavable maleimidocaproyl type linker, to form an antibody-drug conjugate, Rolinsatamab talirine. One Rolinsatamab talirine has an average of 2 site-specific drug attachment engineered cysteines (C242, C242'). The linker equips the valine-alanine dipeptide, as cathepsine B cleavage site. on an average of 2 site-specific drug attachment engineered cysteines (C242, C242') .

HY-P990037

Erzotabart	CD38	Cancer
Erzotabart is an IgG1-kappa, anti-CD38 (ADP-ribosyl cyclase 1, cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, cADPR1) Homo sapiens monoclonal antibody. Erzotabart shows antineoplastic activity .

HY-P99925

Enoticumab REGN421	Notch	Metabolic Disease Cancer
Enoticumab (REGN421, SAR153192) is an IgG1κ antibody targeting human Dll4. DLL4 is a ligand of the Notch signaling pathway and regulates fatty acid uptake through non-transcriptional regulation of macropinocytosis-dependent long-chain fatty acid uptake. Specific in vivo activity of Enoticumab in an ovarian xenograft model. EGN421 (2.5 mg/kg once weekly) resulted in 86% and 83% tumor growth inhibition in mouse subcutaneous TOV-112D or intraperitoneal A2780 human tumor xenograft models, respectively .

HY-P990086

Vopikitug	Interleukin Related	Cancer
Vopikitug is an IgG1-kappa, anti-IL2RA (interleukin 2 receptor alpha subunit, IL-2RA, TAC, p55, CD25) homo sapiens monoclonal antibody. Vopikitug shows antineoplastic activity .

HY-P990251

Anti-Human/Mouse denatured collagen type-I Antibody (XL313)	MMP	Others
Anti-Human/Mouse denatured collagen type-I Antibody (XL313) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to human/mouse denatured collagen type-I.

HY-145626

Ozuriftamab BA302	ADC Antibody	Cancer
Ozuriftamab is a naked human IgG1 kappa antibody of receptor tyrosine kinase-like orphan receptor 2 ROR2, can be used to synthesis ADC .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: